Yıl: 2023 Cilt: 22 Sayı: 2 Sayfa Aralığı: 72 - 75 Metin Dili: İngilizce DOI: 10.4274/uob.galenos.2022.2022.5.2 İndeks Tarihi: 04-07-2023

Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report

Öz:
Objective: This report examined the approaches to low-risk patients using the data from the Urologic Cancer Database - Prostate, Urooncology Association. Materials and Methods: In this study, there were 920 patients with low-risk prostate cancer according to the current guidelines of the European Urology Association. Patient data were obtained from the Urological Cancer Database - Prostate, the Turkish Urooncology Association (UroCaD-P) from records of the years 1995-2021. Ethics committee approval was obtained for this study to publish in the form of a database report. Results: Our study was conducted with 920 patients with low-risk prostate cancer. Therefore, at the time of diagnosis, all patients in the study were ISUP 1, had a prostate specific antigen (PSA) level lower than 10 ng/mL, and clinically T1-T2a. Surgical treatment was used in 750 (81.5%) of the patients. At the time patients were retrieved from the database for the study, 140 patients (15.2%) were in the active surveillance (AS) process. Thirty patients (3.2%) in the study received their local treatment as radiotherapy (RT). The mean age value at cancer detection in the study was 61.9. The mean ages of the patients who were under AS and who underwent radical prostatectomy (RP) were 61.3 and 61.7 years, respectively. In the RT group, the mean age was 66.7 years. The mean PSA value of the whole group was 5.81 ng/mL. While it was 5.94 in AS patients, it was calculated as 5.89 in patients who underwent radical surgery. The mean PSA value of the RT group was 5.40. The pathological upgrade was detected in 225 patients (30%) after surgery. Surgical margin positivity was in 160 of the patients (21.3%) who underwent surgery. In addition, 100 patients (13.3%) had extracapsular disease. The seminal vesicle invasion was detected in 25 patients (3.3%) after surgery. Conclusion: We predict that the incidence of low-risk prostate cancer will increase over time due to the aging of the population, the use of PSA, advances in imaging modalities, and increasing biopsy success rates. Therefore, the importance of the existence of multicentric databases containing this patient group is undeniable. More studies are needed with these databases, including both patient demographics and treatment outcomes. Hopefully, this database report will be an important step in this direction.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol 2019;10:63-89.
  • 2. Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol 2012;30:143-148.
  • 3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
  • 4. Huang J, Vicini FA, Williams SG, et al. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer? Int J Radiat Oncol Biol Phys 2012;83:1141-1148.
  • 5. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.
  • 6. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302:1202-1209.
  • 7. Adolfsson J. Watchful waiting and active surveillance: the current position. BJU Int 2008;102:10-14.
  • 8. Viani GA, Viana BS, Martin JE, et al. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. Cancer 2016;122:2004-2011.
  • 9. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381.
  • 10. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208.
  • 11. Leapman MS, Freedland SJ, Aronson WJ, et al. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol 2016;196:1408-1414.
  • 12. Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden followup study. J Natl Cancer Inst 2010;102:950-958.
  • 13. Arsov C, Becker N, Rabenalt R, et al. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. J Cancer Res Clin Oncol 2015;141:2061-2068.
  • 14. Cohen MS, Hanley RS, Kurteva T, et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international metaanalysis. Eur Urol 2008;54:371-381.
  • 15. Dinh KT, Mahal BA, Ziehr DR, et al. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol 2015;194:343-349.
APA Erbatu O, MÜEZZINOGLU T, Akdoğan B, Aslan G, Sozen T, Baltacı S, SÜER E, Izol V, Üçer O, Ataus S, Türkeri L, Tinay I (2023). Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. , 72 - 75. 10.4274/uob.galenos.2022.2022.5.2
Chicago Erbatu Oguzcan,MÜEZZINOGLU TALHA,Akdoğan Bülent,Aslan Guven,Sozen Tevfik Sinan,Baltacı Sümer,SÜER Evren,Izol Volkan,Üçer Oktay,Ataus Suleyman,Türkeri Levent,Tinay Ilker Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. (2023): 72 - 75. 10.4274/uob.galenos.2022.2022.5.2
MLA Erbatu Oguzcan,MÜEZZINOGLU TALHA,Akdoğan Bülent,Aslan Guven,Sozen Tevfik Sinan,Baltacı Sümer,SÜER Evren,Izol Volkan,Üçer Oktay,Ataus Suleyman,Türkeri Levent,Tinay Ilker Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. , 2023, ss.72 - 75. 10.4274/uob.galenos.2022.2022.5.2
AMA Erbatu O,MÜEZZINOGLU T,Akdoğan B,Aslan G,Sozen T,Baltacı S,SÜER E,Izol V,Üçer O,Ataus S,Türkeri L,Tinay I Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. . 2023; 72 - 75. 10.4274/uob.galenos.2022.2022.5.2
Vancouver Erbatu O,MÜEZZINOGLU T,Akdoğan B,Aslan G,Sozen T,Baltacı S,SÜER E,Izol V,Üçer O,Ataus S,Türkeri L,Tinay I Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. . 2023; 72 - 75. 10.4274/uob.galenos.2022.2022.5.2
IEEE Erbatu O,MÜEZZINOGLU T,Akdoğan B,Aslan G,Sozen T,Baltacı S,SÜER E,Izol V,Üçer O,Ataus S,Türkeri L,Tinay I "Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report." , ss.72 - 75, 2023. 10.4274/uob.galenos.2022.2022.5.2
ISNAD Erbatu, Oguzcan vd. "Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report". (2023), 72-75. https://doi.org/10.4274/uob.galenos.2022.2022.5.2
APA Erbatu O, MÜEZZINOGLU T, Akdoğan B, Aslan G, Sozen T, Baltacı S, SÜER E, Izol V, Üçer O, Ataus S, Türkeri L, Tinay I (2023). Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. Üroonkoloji Bülteni, 22(2), 72 - 75. 10.4274/uob.galenos.2022.2022.5.2
Chicago Erbatu Oguzcan,MÜEZZINOGLU TALHA,Akdoğan Bülent,Aslan Guven,Sozen Tevfik Sinan,Baltacı Sümer,SÜER Evren,Izol Volkan,Üçer Oktay,Ataus Suleyman,Türkeri Levent,Tinay Ilker Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. Üroonkoloji Bülteni 22, no.2 (2023): 72 - 75. 10.4274/uob.galenos.2022.2022.5.2
MLA Erbatu Oguzcan,MÜEZZINOGLU TALHA,Akdoğan Bülent,Aslan Guven,Sozen Tevfik Sinan,Baltacı Sümer,SÜER Evren,Izol Volkan,Üçer Oktay,Ataus Suleyman,Türkeri Levent,Tinay Ilker Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. Üroonkoloji Bülteni, vol.22, no.2, 2023, ss.72 - 75. 10.4274/uob.galenos.2022.2022.5.2
AMA Erbatu O,MÜEZZINOGLU T,Akdoğan B,Aslan G,Sozen T,Baltacı S,SÜER E,Izol V,Üçer O,Ataus S,Türkeri L,Tinay I Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. Üroonkoloji Bülteni. 2023; 22(2): 72 - 75. 10.4274/uob.galenos.2022.2022.5.2
Vancouver Erbatu O,MÜEZZINOGLU T,Akdoğan B,Aslan G,Sozen T,Baltacı S,SÜER E,Izol V,Üçer O,Ataus S,Türkeri L,Tinay I Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report. Üroonkoloji Bülteni. 2023; 22(2): 72 - 75. 10.4274/uob.galenos.2022.2022.5.2
IEEE Erbatu O,MÜEZZINOGLU T,Akdoğan B,Aslan G,Sozen T,Baltacı S,SÜER E,Izol V,Üçer O,Ataus S,Türkeri L,Tinay I "Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report." Üroonkoloji Bülteni, 22, ss.72 - 75, 2023. 10.4274/uob.galenos.2022.2022.5.2
ISNAD Erbatu, Oguzcan vd. "Treatment Options in Low-risk Prostate Cancer Patients: A Retrospective Database Report". Üroonkoloji Bülteni 22/2 (2023), 72-75. https://doi.org/10.4274/uob.galenos.2022.2022.5.2